Research programme: cancer immunotherapeutics - Jounce Therapeutics

Drug Profile

Research programme: cancer immunotherapeutics - Jounce Therapeutics

Alternative Names: ICOS; Inducible T cell co-stimulator; JTX 4014; myeloid-functional TIM-3 antibodies

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jounce Therapeutics
  • Class Bispecific antibodies; Cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Jun 2017 Jounce in-licenses gene delivery technology from OncoSec Medical
  • 25 Apr 2015 Preclinical trials in Cancer in USA (unspecified route)
  • 14 Feb 2013 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top